Protocol Ledger

NCT04759248 · Phase II · ACTIVE NOT RECRUITING

Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer

Interventional Phase II clinical trial protocol NCT04759248 sponsored by SOLTI Breast Cancer Research Group in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-03-15 Enrollment: 55 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04759248
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)55 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04759248
Protocol FieldVerified Registry Value
NCT IdentifierNCT04759248
Consolidated Lead SponsorSOLTI Breast Cancer Research Group
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment55 participants (ESTIMATED)
Registered Start Date2021-03-15
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04759248
Hospital Research SiteLocationSite Profile
Hospital del MarBarcelona, SpainOpen Hospital Dossier ->
Hospital General Universitario de AlicanteAlicante, SpainOpen Hospital Dossier ->
Hospital Clinic de BarcelonaBarcelona, SpainOpen Hospital Dossier ->
Hospital Universitari Vall d'HebronBarcelona, SpainOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI